Table 3.
Antibiotic Exposure and Use Histories of Patients with Hospital-Acquired and Non-Hospital-Acquired KP BSI
| Non-Hospital-Acquired (n=106) | Hospital-Acquired (n=171) | χ2 | P valuea | |
|---|---|---|---|---|
| Antibiotic exposure | ||||
| Any antibiotics | 30(28.3%) | 113(66.1%) | 37.399 | <0.001 |
| Carbapenems | 5(4.7%) | 65(38.0%) | 38.412 | <0.001 |
| Glycopeptides | 7(6.6%) | 43(25.1%) | 15.210 | <0.001 |
| Quinolones | 6(5.7%) | 27(15.8%) | 6.398 | 0.011 |
| Cephalosporins | 5(4.7%) | 37(21.6%) | 14.564 | <0.001 |
| BLBLIs | 7(6.6%) | 75(43.9%) | 43.584 | <0.001 |
| Aminoglycosides | 0 | 3(1.8%) | 0.599 | 0.439 |
| Linezolid | 1(0.9%) | 9(5.3%) | 2.377 | 0.123 |
| Tigecycline | 2(1.9%) | 18(10.5%) | 7.291 | 0.007 |
| Nitroimidazoles | 0 | 5(2.9%) | 1.722 | 0.189 |
| TMP-SMZ | 0 | 10(5.8%) | 4.860 | 0.027 |
| Minocycline | 1(0.9%) | 6(3.5%) | 0.862 | 0.353 |
| Antifungal agents | 3(2.8%) | 42(24.6%) | 22.712 | <0.001 |
| Antibiotic useb | ||||
| Use Carbapenems | 75(70.8%) | 111(64.9%) | 1.013 | 0.314 |
| Use Quinolones | 22(20.8%) | 25(14.6%) | 1.748 | 0.186 |
| Use Cephalosporins | 19(17.9%) | 23(13.5%) | 1.018 | 0.313 |
| Use BLBLIs | 65(61.3%) | 74(43.3%) | 8.524 | 0.004 |
| Use Tigecycline | 8(7.5%) | 51(29.8%) | 19.373 | <0.001 |
| Use Amikacin | 10(9.4%) | 20(11.7%) | 0.347 | 0.556 |
| Use Minocycline | 10(9.4%) | 18(10.5%) | 0.086 | 0.769 |
| Use fosfomycin | 7(6.6%) | 2(1.2%) | 4.540 | 0.033 |
| Use Nitroimidazoles | 8(7.5%) | 5(2.9%) | 2.179 | 0.140 |
| Use TMP-SMZ | 1(0.9%) | 12(7.0%) | 4.125 | 0.042 |
| Use Ceftazidime-avibactam | 0 | 7(4.1%) | 2.945 | 0.086 |
| Use polymyxin B | 0 | 6(3.5%) | 2.326 | 0.127 |
| Early appropriate therapyc | 94(88.7%) | 102(59.6%) | 26.653 | <0.001 |
Notes: aP values less than 0.05 are bolded; bThe antibiotics selected for the first time were consistent with the antimicrobial susceptibility testing; cIt refers to all antibiotics that have been used for more than 48 hours after the start of BSI.
Abbreviations: TMP-SMZ, trimethoprim-sulfamethoxazole; BLBLIs, β-lactam/β-lactamase inhibitor combinations.